title: A-phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma. A Southwest Oncology Group study.
abstract: Thirty-three patients with relapsing or refractory multiple myeloma were treated with 6-Thioguanine (6TG) at a dose of 1 g/M2, with therapy given over four hours every three weeks. The major toxicity seen was myelotoxicity; thrombocytopenia was more commonly noted than neutropenia. One patient achieved a PR, two were clinically improved. 6TG in this short infusion schedule proved to be myelotoxic, but demonstrated little activity in previously treated myeloma patients.
authors.affiliation: Wayne State University Medical Center, Seattle.
authors.forename: M B
authors.initials: MB
authors.lastname: Edelstein
authors.forename: J J
authors.initials: JJ
authors.lastname: Crowley
authors.forename: F A
authors.initials: FA
authors.lastname: Valeriote
authors.forename: J D
authors.initials: JD
authors.lastname: Bonnet
authors.forename: J O
authors.initials: JO
authors.lastname: Carden
authors.forename: R C
authors.initials: RC
authors.lastname: Khanna
authors.forename: S E
authors.initials: SE
authors.lastname: Salmon
authors.forename: J S
authors.initials: JS
authors.lastname: Ungerleider
mesh_terms: D004341:Drug Evaluation; D006801:Humans; D007262:Infusions, Intravenous; D009101:Multiple Myeloma / Q000188:drug therapy*; D013866:Thioguanine / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity
chemical_list: D013866:Thioguanine